SCHEMBL20239169

SCHEMBL20239169

CNS(=O)(=O)Cc1ccc(Oc2cc(CNc3ncc(Cl)cn3)nc(C(F)(F)F)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.54
KDM4E B2RXH2 3/20 0.35
ATM Q13315 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
LMNA P02545 3/20 0.33
POLB P06746 1/20 0.33
BLM P54132 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LIPE Q05469 1/20 0.32
MAPT P10636 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
VNN1 O95497 2/20 0.32
CNR2 P34972 1/20 0.32
DAGLA Q9Y4D2 1/20 0.31
CYP3A4 P08684 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239322 0.91 DGAT2 (0.44) DGAT2KDM4EATMLMNAPOLB
SCHEMBL16738674 0.87 DGAT2 (0.57) DGAT2KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL20239333 0.86 DGAT2 (0.56) DGAT2KDM4ECYP2C9LMNAMAPT
SCHEMBL20239203 0.86 DGAT2 (0.59) DGAT2KDM4ECYP2C9LMNASMN1; SMN2
SCHEMBL20239171 0.85 DGAT2 (0.56) DGAT2KDM4ECYP2C9LMNAMAPT
SCHEMBL20239227 0.85 DGAT2 (0.56) DGAT2KDM4ECYP2C9LMNAMAPT
SCHEMBL20239176 0.84 DGAT2 (0.55) DGAT2KDM4ECYP2C9LMNAPOLB
SCHEMBL18249757 0.84 DGAT2 (0.54) DGAT2KDM4ELMNASMN1; SMN2VNN1
SCHEMBL20239272 0.83 DGAT2 (0.55) DGAT2KDM4ECYP2C9SMN1; SMN2VNN1
SCHEMBL20239248 0.82 SMN1; SMN2 (0.43) DGAT2KDM4EATMCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885KDM4E 4070/4885ATM 2434/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885KDM4E 3891/4885ATM 2513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.